Respiratory Disorders Market

Respiratory Disorders Market by Type of Product (Novel Drugs, Smart Drug Delivery Devices), 2018 - 2030

  • Lowest Price Guaranteed From USD 3,499

  • Companies Covered
    160

  • Pages
    468

  • View Count
    27341

Smart Devices for Respiratory Disorders Market Overview

The respiratory disorders market is estimated to be worth $5 billion in 2018 and is expected to grow at compounded annual growth rate (CAGR) of 14.7% during the forecast period. According to the Forum of International Respiratory Societies, around 4 million individuals die each year due to chronic respiratory diseases. The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory diseases, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. Specifically, COPD is currently known to be the fourth leading cause of death worldwide. According to the data provided by the WHO, more than 3 million people die annually from COPD; this represents a total of 6% of the global annual deaths. Around 90% of these deaths occur in low and middle-income countries. Asthma, on the other hand, is more common in pediatric population. Asthma alone results in more than 30% of pediatric hospitalizations. Moreover, it is responsible for around 180,000 annual deaths worldwide.

In addition to asthma and COPD, other chronic respiratory disorders are also associated with high unmet needs. Specifically, the patients suffering from cystic fibrosis, which is known to have a global prevalence of 70,000, have reported median lifespan of less than 30 years. In addition, the patients suffering from cystic fibrosis are at a relatively higher risk of acquiring life threatening lung infections. The high prevalence, high rate of hospitalization and high cost of treatment for these disorders places a huge burden on the society in terms of direct healthcare costs and the loss of productivity associated with disability and premature mortality of the patients.

Although these diseases cannot be cured, government agencies and big pharma companies have made significant investments in R&D to improve disease management and address the unmet needs. These investments and development initiatives have led to the approval of several therapies, such as LAMA / LABA fixed dose combinations, ICS / LAMA / LABA fixed combinations, CFTR modulators, and novel biologics and antibiotics, which have helped improve the quality of life of patients. The industry is gradually transitioning towards the development of more targeted therapies. This shift is facilitating a scenario, wherein therapeutic strategies are changing from broad spectrum remedies to those that target individual patient segments.

Key Companies in Respiratory Disorders Market

Examples of key companies engaged in respiratory disorders market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline, Novartis, Teva Pharmaceutical, Vertex Pharmaceuticals, CURx Pharmaceuticals, Laurent Pharmaceuticals, Sanofi, Gilead Sciences and AB Science. This market report includes an easily searchable excel database of all the companies providing novel drugs and smart devices for respiratory disorders, worldwide.

Scope of the Report

The ‘Respiratory Disorders Market, 2018-2030’ market report provides a comprehensive study on the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the respiratory disorders market. The field has captured the interest of several drug developers, both small and large companies. With several novel drug candidates in development, we anticipate the respiratory disorders market to witness continued market growth during the forecast period. Amongst other elements, the market research report features:

  • A discussion on the novel therapies under development for the treatment of asthma, COPD and cystic fibrosis. The report provides information on the developers, phase of development of candidate drugs / therapies, mechanism of action, route of administration, type of molecule, type of formulation and the dose frequency of the various therapies.
  • An analysis highlighting the key unmet needs across asthma, COPD and cystic fibrosis. The study presents insights generated from real-time data on unmet needs identified from social media posts, recent publications, patient blogs and discussions of key opinion leaders.
  • An extensive review of the development portfolio and key initiatives undertaken by established players (players with approved / late-stage drug candidates). This section also provides an overview of the companies, their financial performance, recent collaborations and a comprehensive future outlook.
  • Elaborate profiles of marketed and phase III drugs; each profile features an overview of the drug, its mechanism of action, dosage information, details on the cost and sales (wherever available), clinical development plan, and key clinical trial results.
  • An assessment of the key players involved in the development of smart inhalers. It provides information on the development status of the inhalers, type of inhalers and the key collaborators. In addition, the report provides a comparative assessment of the various smart inhalers on the basis of several parameters, such as availability of Bluetooth, USB connection, reminder function and rechargeable options.
  • A discussion on the regulatory landscape for the approval of combination products (drugs and inhalers), as well as smart inhalers in different countries.
  • Detailed analysis of the key trends (for instance, relative start-up activity) in the development of novel therapies across asthma, COPD and cystic fibrosis.

The key objective of respiratory disorders market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for respiratory disorders market during the forecast period. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the forecast period 2018-2030. The research, analysis and insights presented in this market research report include potential sales of novel therapies, as well as smart inhalers that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the market report were influenced by discussions with senior stakeholders in the respiratory disorders market. These include Antonio Anzueto (Pulmonologist, University of Texas Health Science Center), Richard Moss (Pediatric Pulmonologist, Lucile Packard Children’s Hospital, Stanford University), Alex Stenzler (Founder and President, Novoteris), Dinesh Srinivasan (Director, Anthera Pharmaceuticals) and Dinu Sen (CEO, CURx Pharmaceuticals). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What are the most common types of respiratory disorders?

Answer: Most common respiratory disorders include asthma, COPD, cystic fibrosis, emphysema, pulmonary hypertension and tuberculosis.

Question 2: How big is the respiratory disorders market?

Answer: The respiratory disorders market size is estimated to be worth $5 billion in 2018.

Question 3: What is the projected market growth of the respiratory disorders market?

Answer: The respiratory disorders market is expected to grow at compounded annual growth rate (CAGR) of 14.7% during the forecast period 2018 - 2030.

Question 4: Who are the leading players in the respiratory disorders industry?

Answer: AbbVie, AstraZeneca, Boehringer Ingelheim, Chiesi Pharmaceuticals, GlaxoSmithKline, Novartis, Teva Pharmaceutical, Vertex Pharmaceuticals, CURx Pharmaceuticals, Laurent Pharmaceuticals, Sanofi, Gilead Sciences and AB Science.

Question 5: How many novel drug candidates are currently being evaluated for the treatment of respiratory disorders worldwide?

Answer: Around 135 novel drug candidates are being evaluated across various stages of development for the treatment of patients suffering from respiratory disorders worldwide.

Question 6: How many players are currently engaged in the respiratory disorders industry?

Answer: Presently, around 90 players are engaged in the respiratory disorders market.

Question 7: How many drugs have been approved for the treatment of respiratory disorders over the last few years?

Answer: In the last few years, four biologics have been approved for the treatment of severe form of asthma. These are FASENRA™ (2017), CINQAIR™ (2016), XOLAIR® (2016, for pediatric patients) and NUCALA® (2015).

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com